Clinical Trial Finds Tirzepatide Lowers BMI in Adolescents with Obesity
A recent Phase III clinical trial evaluated the once-weekly injectable drug tirzepatide in teenagers with obesity, revealing significant reductions in body mass index and improvements in metabolic health markers over 72 weeks.
🏃FitnessPhoto: Medical Xpress
Key points
- Phase III SURMOUNT-ADOLESCENTS trial tested tirzepatide across 160 teenagers in six countries.
- Participants on the drug saw an average BMI reduction of 18.5% over 72 weeks.
- Over half of the teenagers taking tirzepatide moved below the clinical obesity threshold.
A recent Phase III clinical trial, designated SURMOUNT-ADOLESCENTS, evaluated the effectiveness of the once-weekly injectable medication tirzepatide in teenagers struggling with obesity or overweight conditions accompanied by related health complications. Conducted across 31 medical centers in six countries including the U.S., Canada, and Italy, the study enrolled 160 participants aged 12 to under 18. Patients were randomly assigned to receive either weekly injections of tirzepatide or a placebo, alongside lifestyle counseling focused on balanced nutrition and physical activity.
After 72 weeks of treatment, adolescents receiving tirzepatide experienced an average BMI reduction of 18.5%, contrasted with a 0.5% increase in the placebo group. Furthermore, approximately 54% of the participants taking the dual-action medication moved below the clinical obesity threshold for their age and sex, compared to just 7% of those given the placebo. Trial data also indicated improvements in physical comfort during daily tasks and favorable shifts in blood markers, including reduced blood pressure and improved cholesterol profiles.
The study highlights important considerations regarding safety and scope, as roughly 81.5% of the treatment group experienced mostly mild to moderate digestive side effects. Researchers also noted that adolescent height growth and puberty progression continued normally throughout the study period. Because obesity is a complex chronic condition affecting roughly one in five teenagers in the U.S., clinical experts emphasize that pharmacological options are generally studied as an addition to, rather than a replacement for, lifestyle interventions.
What to know: Tirzepatide mimics natural gut hormones to help regulate appetite and blood sugar, but like all medical therapies, it carries potential side effects and requires professional oversight. Readers should consult a qualified healthcare provider for personalized medical advice regarding adolescent weight management.
Source Medical Xpress — medicalxpress.com/news/2026-11-tirzepatide-teens-obesity-threshold-clin… ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…